Mario Agramonte-Vilca, Karol Moscol-Chavez, Lourdes Aranda-Gomero, Alfredo Wong-Chang, Stalin Vilcarromero, Cesar Copaja-Corzo
{"title":"Mortality and associated factors in post-stem cell transplant patients: a two-year cohort in a public hospital in Peru.","authors":"Mario Agramonte-Vilca, Karol Moscol-Chavez, Lourdes Aranda-Gomero, Alfredo Wong-Chang, Stalin Vilcarromero, Cesar Copaja-Corzo","doi":"10.17843/rpmesp.2025.423.14389","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective.: </strong>To determine mortality and associated factors in patients who received an allogeneic hematopoietic stem cell transplant at the Hospital Nacional Edgardo Rebagliati Martins, between January 2017 and December 2022.</p><p><strong>Materials and methods.: </strong>A retrospective cohort study was conducted on patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) between 2017 and 2022. Death at one hundred days and two years, and its associated factors, were evaluated. Proportional Cox regression models were used.</p><p><strong>Results.: </strong>342 post-HSCT patients were included, with a median age of 23 years (interquartile range: 10 to 39), of whom 53.5% were women. The most frequent diagnosis for the transplant was acute lymphoblastic leukemia at 54.1%. Mortality in the first 100 days post-HSCT was 8.2%, and at two years was 30.4%. In the multivariate regression at one hundred days, factors associated with a higher risk of mortality were age over 50 years (HRa: 6.97; 95% CI: 1.18-41.23), being a recipient of a haploidentical transplant (HRa: 3.57; 95% CI: 1.13-11.24), and sepsis as a complication (HRa: 68.78; 95% CI: 19.32-244.84). In the two-year analysis, acute myeloid leukemia (1.72; IC 95%: 1.08-2.74), haploidentical transplant (HRa:1.81; 95%CI: 1.21-2.72), and disease relapse (HRa: 4.17; 95%CI%: 2.75-6.31) were associated with a higher risk of death.</p><p><strong>Conclusions.: </strong>The mortality found was low and similar to that of countries with higher incomes; however, it is necessary to formulate interventions that reduce the incidence of modifiable factors such as sepsis.</p>","PeriodicalId":53651,"journal":{"name":"Revista Peruana de Medicina de Experimental y Salud Publica","volume":"42 3","pages":"252-262"},"PeriodicalIF":1.1000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12679968/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Peruana de Medicina de Experimental y Salud Publica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17843/rpmesp.2025.423.14389","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Objective.: To determine mortality and associated factors in patients who received an allogeneic hematopoietic stem cell transplant at the Hospital Nacional Edgardo Rebagliati Martins, between January 2017 and December 2022.
Materials and methods.: A retrospective cohort study was conducted on patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) between 2017 and 2022. Death at one hundred days and two years, and its associated factors, were evaluated. Proportional Cox regression models were used.
Results.: 342 post-HSCT patients were included, with a median age of 23 years (interquartile range: 10 to 39), of whom 53.5% were women. The most frequent diagnosis for the transplant was acute lymphoblastic leukemia at 54.1%. Mortality in the first 100 days post-HSCT was 8.2%, and at two years was 30.4%. In the multivariate regression at one hundred days, factors associated with a higher risk of mortality were age over 50 years (HRa: 6.97; 95% CI: 1.18-41.23), being a recipient of a haploidentical transplant (HRa: 3.57; 95% CI: 1.13-11.24), and sepsis as a complication (HRa: 68.78; 95% CI: 19.32-244.84). In the two-year analysis, acute myeloid leukemia (1.72; IC 95%: 1.08-2.74), haploidentical transplant (HRa:1.81; 95%CI: 1.21-2.72), and disease relapse (HRa: 4.17; 95%CI%: 2.75-6.31) were associated with a higher risk of death.
Conclusions.: The mortality found was low and similar to that of countries with higher incomes; however, it is necessary to formulate interventions that reduce the incidence of modifiable factors such as sepsis.
期刊介绍:
La Revista Peruana de Medicina Experimental y Salud Pública (RPMESP) es el órgano oficial de difusión científica del Instituto Nacional de Salud (INS) del Perú. Es una publicación arbitrada por pares, de periodicidad trimestral, de ámbito y difusión mundial, indizada en MEDLINE/Index Medicos, SCOPUS, EMBASE, SciELO Salud Pública y otras bases de datos internacionales. La RPMESP es distribuida en su versión impresa y electrónica, con acceso gratuito a texto completo. La RPMESP publica artículos referidos a temas del ámbito biomédico y de salud pública, resaltando aportes prácticos, que contribuyan a mejorar la situación de salud del país y de la región. Propicia el intercambio de la experiencia científica en salud entre instituciones y personas dedicadas a la investigación dentro y fuera del Perú a fin de promover el avance y la aplicación de la investigación en salud.